First Author: I.Perente TURKEY
Co Author(s): A. Vural D. Ekinci U. Onur Z. Seymen
Back to previous
To investigate the extent of vascularization of the peripheral retina and vascular development patterns in patients with type 1 Retinopathy of Prematurity (ROP) in zone I and posterior zone II who were treated with a single intravitreal injection of bevacizumab 0.025 ml (0.625mg), and in patients with type 2 ROP who were followed without treatment. The progress of ROP was evaluated with fluorescein angiographic findings in patients with type 1 and type 2 ROP.
this is a retrospective descriptive study
Medical records of the patients who undergone single dose of intravitreal bevacizumab injection treatment for zone I and posterior zone II type 1 ROP and type 2 ROP without any treatment were studied. All of the patients were examined with RetCam III (Clarity Medical Systems, Pleasanton, CA) under general anaesthesia and using a contact gel. Wide-angle coloured fundus images of the retina and corresponding FAs were captured bilaterally for all babies.
74 eyes of 37 premature infants were included in the study; 48 eyes of 24 patients were treated for type 1 ROP and 26 eyes of 13 patients were diagnosed as type 2 ROP. On the FA examination vascular terminal was found to be in zone 2 in 10 eyes of 5 patients (20.8%), in zone 3 with more then 2 disc diameters (DD) from temporal ora serrata in 16 eyes of 8 patients (33.3%), in zone 3 with less then 2 DD from temporal ora serrata in 22 eyes of 11 patients (45.8%) in type 1 ROP group. In all eyes of type 2 ROP group (100%), vascular terminal was in zone 3 with less then 2 DD from temporal ora serrata. We noted circumferential vessels in 19 eyes of 10 patients In type 1 group and 4 eyes of 2 patients in type 2 group; closely packed multiple bridging arteriovenous shunts in 6 eyes of 3 patient In type 1 group and in 3 eyes of 3 patients In type 2 group; irregular arteriolar branching in 3 eyes of 2 patient In type 1 group and in 13 eyes of 7 patients In type 2 group.
Peripheral vascular abnormalities can be detected both in type 1 and type 2 ROP patients. Anti-VEGF drugs slow down vascularization as they reduced VEGF level but if enough time passes vascularization can reach the farthermost limits at the end.